Results 1 to 10 of about 6,786 (213)

Geographic Variation in the Use of Gabapentinoids and Opioids for Pain in a Commercially Insured Adult Population in the United States

Journal of Pain Research, 2022
Danni Zhao,1 Jonggyu Baek,1 Anne L Hume,2,3 Emily A McPhillips,1 Kate L Lapane1 1Department of Population and Quantitative Health Sciences, UMass Chan Medical School, Worcester, MA, USA; 2Department of Family Medicine, Alpert Medical School, Brown ...
Kate L Lapane, Anna Hume, Jonggyu Baek
exaly   +4 more sources

Prevalence and Predictors of Substance Use Disorder Due to Gabapentinoids in Patients With Chronic Non‐Cancer Pain: A Cross‐Sectional Study [PDF]

Health Science Reports
Background and Aims The increase in the use of gabapentinoids in the treatment of patients with chronic non‐cancer pain (CNCP) has drawn attention to the possibility of substance use disorder (SUD) due to gabapentinoids.
Neele Kufeld, Klaus Weckbecker, Eva Münster, Norbert Scherbaum, Michael Specka, Johannes Just   +5 more
doaj   +3 more sources

Opioids and Gabapentinoids Utilisation and Their Related-Mortality Trends in the United Kingdom Primary Care Setting, 2010–2019: A Cross-National, Population-Based Comparison Study [PDF]

Frontiers in Pharmacology, 2021
Background: There is growing concern over the increasing utilisation trends of opioids and gabapentinoids across but there is lack of data assessing and comparing the utilisation trends across the four United Kingdom countries.
Amanj Kurdi
exaly   +4 more sources

Gabapentinoids-Related Delirium Adverse Events: A Real-World Study From 2004 to 2022 Based on FAERS [PDF]

Journal of Pain Research
Zhongbiao Nie,1 Cuilv Liang,2 Zhihong Li,1 Xinqiang Han,3 Ran Zhang4 1Department of Pharmacy, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, People’s ...
Ran Zhang
exaly   +3 more sources

Possible Signals of Ocular Disorders Associated with Gabapentinoids: A Three-Arm Study [PDF]

Pharmaceuticals
Background: Gabapentinoids (gabapentin and pregabalin) are medications used to treat epilepsy and diabetic neuropathy. Reports of gabapentinoid-associated adverse drug reactions (ADRs) are increasing.
Mya Murray, Amira Guirguis, Paul Deslandes, John Martin Corkery, Stefania Chiappini, Mariacristina Parravano, Fabrizio Schifano   +6 more
doaj   +4 more sources

Sustained postoperative gabapentinoids do not result in clinically important decreases in postoperative delirium, pain, or opioid dose in gabapentin naïve lumbar fusion patients [PDF]

North American Spine Society Journal
: Background: By decreasing postoperative pain and opioids, sustained postoperative gabapentinoids might decrease delirium after spine surgery. Prior randomized trials of sustained postoperative gabapentinoids after spine surgery have either not assessed
Emanuel J. Ray, BS, Eli A. Perez, MD, Ryan M. Carnahan, PharmD, MS, Catherine R. Olinger, MD, Royce W. Woodroffe, MD, Brian J. Park, MD, Colin J. Gold, MD, Rashmi N. Mueller, MD, Matthew I. Banks, PhD, Robert D. Sanders, MBBS, PhD, Bradley J. Hindman, MD   +10 more
doaj   +2 more sources

How the Reclassification of Gabapentinoids Reshaped Neuropathic Pain Treatment in Saudi Arabia: A Survey of Healthcare Professionals [PDF]

Pain and Therapy
Introduction This study aimed to assess knowledge gaps, perceptions, and prescribing approaches of healthcare professionals (HCPs) in Saudi Arabia regarding pain management, particularly neuropathic pain, in the context of recent reclassification of ...
Abdullah Kaki, Yousef Hamdy, Ashraf Amir
doaj   +2 more sources

Association Between the Use of Gabapentinoids and Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis [PDF]

Current Therapeutic Research
Background: Evidence on gabapentinoids and its respiratory safety among the patients with chronic obstructive pulmonary disease(COPD) or asthma are remains uncertain. Objective: To evaluate the risk of exacerbations with gabapentinoids.
Ranakishor Pelluri, MPharm, PhD, Lalasa Sri Tulasi Royyuru, PharmD, Suresh Varukolu, MPharm, Paul Kitonga Muteti, BPharm, Birungi Mariam Nalukenge, BPharm, Sravani Thommandru, PharmD, Buchi Naidu Nalluri, MPharm, PhD, Prasada Chowdari Gurram, MPharm, PhD, Bhima Sridevi, MPharm, PhD, Blessy Chittelu, PharmD, Vanitha Rani Nagasubramanian, MPharm, PhD, Uday Venkat Mateti, PharmD, PhD, Ananthesh L, MPharm, Ramya Rachamanti, MBBS, MD, Nageswari Patnam, MPharm, PhD, Kannan Gopal, MPharm, PhD   +15 more
doaj   +2 more sources

Trends in Co-Prescribing Opioids and Gabapentinoids Among Medicare Beneficiaries, 2017 to 2022 [PDF]

Medical Sciences
Background: Co-prescribing opioids and gabapentinoids (GABA, gabapentin and pregabalin) is associated with increased risk of falls, fractures, opioid overdose and deaths.
Mukaila Raji, Aashnika Sujit, Jordan Westra, Shilpa Rajagopal, Yong-Fang Kuo   +4 more
doaj   +2 more sources

Lack of impact of OCTN1 gene polymorphisms on clinical outcomes of gabapentinoids in Pakistani patients with neuropathic pain.

PLoS ONE, 2022
Background and objectiveGabapentinoids are the first-line drugs for neuropathic pain. These drugs are the substrate of organic cation transporter (OCTN1) for renal excretion and absorption across the intestinal epithelium.
Abida Shaheen, Syed Mahboob Alam, Fahad Azam, Salman Ahmad Saleem, Moosa Khan, Syed Saud Hasan, Afrose Liaquat   +6 more
doaj   +2 more sources